FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947648853> ?p ?o ?g. }

• W2947648853 endingPage "276" @default.
• W2947648853 startingPage "276" @default.
• W2947648853 abstract "276 Background: Ipilimumab and nivolumab (IPI-NIVO) and IO/vascular endothelial growth factor (VEGF) inhibitor combinations (IOVE) are now standard of care 1L treatment options for mRCC. However, there is limited head-to-head comparative evidence between these strategies. Methods: Using the IMDC dataset, patients treated with a 1L IOVE combination (pembrolizumab axitinib, avelumab axitinib and nivolumab cabozantinib) were compared with those treated with IPI-NIVO. The outcomes of interest were overall response rate (ORR), treatment duration (TD), time to next treatment (TTNT), and overall survival (OS). A preplanned subgroup analysis of the IMDC intermediate/poor risk population was conducted. Hazard ratios were adjusted for IMDC risk factors. Results: 723 patients were included for analysis (N=571 for IPI-NIVO and N=152 for IOVE). The median age was 60 in both groups. The proportion of patients with IMDC favorable, intermediate and poor risk disease in IPI-NIVO vs. IOVE groups were 9% vs. 33%, 58% vs. 53%, 33% vs. 14%, respectively. In the intermediate/poor risk groups (Table), ORR and median TD were lower and shorter in IPI-NIVO vs IOVE while no difference in median TTNT and OS was detected. The HR for death adjusting for IMDC criteria for IPI-NIVO vs. IOVE was 0.92 (95% CI 0.61-1.40, p=0.71). IMDC risk groups and the presence or absence of sarcomatoid histology, brain, liver or bone metastases were not associated with differences in OS between these treatments (all p>0.2). Patients that had dose delays or steroid use (defined as >40mg of prednisone equivalent/day) for immune related adverse events (irAEs) were associated with longer median TTNT (21.6 vs. 9.5 mons, p=0.02) and OS (NR vs. 44.4 mons, p=0.01) despite similar treatment durations (7.6 vs. 8.9 mons, p=0.77) compared to those without dose delays or steroid use. Conclusions: We were unable to detect any differences in OS between IPI-NIVO and IOVE regimens in the IMDC intermediate/poor risk groups and amongst various subgroups. Patients who experienced irAEs requiring dose delay or steroids had longer overall survival. [Table: see text]" @default.
• W2947648853 created "2019-06-07" @default.
• W2947648853 creator A5000275497 @default.
• W2947648853 creator A5011946923 @default.
• W2947648853 creator A5028260078 @default.
• W2947648853 creator A5029480022 @default.
• W2947648853 creator A5030964546 @default.
• W2947648853 creator A5036213851 @default.
• W2947648853 creator A5037495975 @default.
• W2947648853 creator A5037646183 @default.
• W2947648853 creator A5041033274 @default.
• W2947648853 creator A5052504518 @default.
• W2947648853 creator A5054850662 @default.
• W2947648853 creator A5057831510 @default.
• W2947648853 creator A5058154486 @default.
• W2947648853 creator A5058325420 @default.
• W2947648853 creator A5059200225 @default.
• W2947648853 creator A5063838757 @default.
• W2947648853 creator A5064732405 @default.
• W2947648853 creator A5077514210 @default.
• W2947648853 creator A5087150696 @default.
• W2947648853 creator A5088471004 @default.
• W2947648853 date "2021-02-20" @default.
• W2947648853 modified "2023-10-14" @default.
• W2947648853 title "Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)." @default.
• W2947648853 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.276" @default.
• W2947648853 hasPublicationYear "2021" @default.
• W2947648853 type Work @default.
• W2947648853 sameAs 2947648853 @default.
• W2947648853 citedByCount "9" @default.
• W2947648853 countsByYear W29476488532021 @default.
• W2947648853 countsByYear W29476488532022 @default.
• W2947648853 countsByYear W29476488532023 @default.
• W2947648853 crossrefType "journal-article" @default.
• W2947648853 hasAuthorship W2947648853A5000275497 @default.
• W2947648853 hasAuthorship W2947648853A5011946923 @default.
• W2947648853 hasAuthorship W2947648853A5028260078 @default.
• W2947648853 hasAuthorship W2947648853A5029480022 @default.
• W2947648853 hasAuthorship W2947648853A5030964546 @default.
• W2947648853 hasAuthorship W2947648853A5036213851 @default.
• W2947648853 hasAuthorship W2947648853A5037495975 @default.
• W2947648853 hasAuthorship W2947648853A5037646183 @default.
• W2947648853 hasAuthorship W2947648853A5041033274 @default.
• W2947648853 hasAuthorship W2947648853A5052504518 @default.
• W2947648853 hasAuthorship W2947648853A5054850662 @default.
• W2947648853 hasAuthorship W2947648853A5057831510 @default.
• W2947648853 hasAuthorship W2947648853A5058154486 @default.
• W2947648853 hasAuthorship W2947648853A5058325420 @default.
• W2947648853 hasAuthorship W2947648853A5059200225 @default.
• W2947648853 hasAuthorship W2947648853A5063838757 @default.
• W2947648853 hasAuthorship W2947648853A5064732405 @default.
• W2947648853 hasAuthorship W2947648853A5077514210 @default.
• W2947648853 hasAuthorship W2947648853A5087150696 @default.
• W2947648853 hasAuthorship W2947648853A5088471004 @default.
• W2947648853 hasConcept C121608353 @default.
• W2947648853 hasConcept C126322002 @default.
• W2947648853 hasConcept C143998085 @default.
• W2947648853 hasConcept C207103383 @default.
• W2947648853 hasConcept C2776539811 @default.
• W2947648853 hasConcept C2777472916 @default.
• W2947648853 hasConcept C2777701055 @default.
• W2947648853 hasConcept C2779490328 @default.
• W2947648853 hasConcept C2780030458 @default.
• W2947648853 hasConcept C2781433595 @default.
• W2947648853 hasConcept C2908647359 @default.
• W2947648853 hasConcept C44249647 @default.
• W2947648853 hasConcept C71924100 @default.
• W2947648853 hasConcept C99454951 @default.
• W2947648853 hasConceptScore W2947648853C121608353 @default.
• W2947648853 hasConceptScore W2947648853C126322002 @default.
• W2947648853 hasConceptScore W2947648853C143998085 @default.
• W2947648853 hasConceptScore W2947648853C207103383 @default.
• W2947648853 hasConceptScore W2947648853C2776539811 @default.
• W2947648853 hasConceptScore W2947648853C2777472916 @default.
• W2947648853 hasConceptScore W2947648853C2777701055 @default.
• W2947648853 hasConceptScore W2947648853C2779490328 @default.
• W2947648853 hasConceptScore W2947648853C2780030458 @default.
• W2947648853 hasConceptScore W2947648853C2781433595 @default.
• W2947648853 hasConceptScore W2947648853C2908647359 @default.
• W2947648853 hasConceptScore W2947648853C44249647 @default.
• W2947648853 hasConceptScore W2947648853C71924100 @default.
• W2947648853 hasConceptScore W2947648853C99454951 @default.
• W2947648853 hasIssue "6_suppl" @default.
• W2947648853 hasLocation W29476488531 @default.
• W2947648853 hasOpenAccess W2947648853 @default.
• W2947648853 hasPrimaryLocation W29476488531 @default.
• W2947648853 hasRelatedWork W3056885861 @default.
• W2947648853 hasRelatedWork W3080692347 @default.
• W2947648853 hasRelatedWork W4221029189 @default.
• W2947648853 hasRelatedWork W4226292283 @default.
• W2947648853 hasRelatedWork W4293768144 @default.
• W2947648853 hasRelatedWork W4328097671 @default.
• W2947648853 hasRelatedWork W4377100578 @default.
• W2947648853 hasRelatedWork W4380151496 @default.
• W2947648853 hasRelatedWork W4386391749 @default.
• W2947648853 hasRelatedWork W4386816258 @default.
• W2947648853 hasVolume "39" @default.
• W2947648853 isParatext "false" @default.

• next